BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37094128)

  • 21. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
    Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
    Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMARCA4 vulnerability in H3K27M midline glioma: A silver bullet for a lethal disease.
    Chen CCL; Andrade AF; Jabado N
    Mol Cell; 2023 Jan; 83(2):163-164. PubMed ID: 36669477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
    Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
    Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
    Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
    Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
    Chan KM; Han J; Fang D; Gan H; Zhang Z
    Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
    Reichl KD; Lee ECY; Gopalsamy A
    Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
    Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
    Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
    Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
    Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SWI/SNF complex-deficient soft tissue neoplasms: An update.
    Schaefer IM; Hornick JL
    Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
    Sanders LM; Cheney A; Seninge L; van den Bout A; Chen M; Beale HC; Kephart ET; Pfeil J; Learned K; Lyle AG; Bjork I; Haussler D; Salama SR; Vaske OM
    Gigascience; 2020 Dec; 9(12):. PubMed ID: 33319914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Interactions between the Human T-Cell Leukemia Virus Type 1 Antisense Protein HBZ and the SWI/SNF Chromatin Remodeling Family: Implications for Viral Life Cycle.
    Alasiri A; Abboud Guerr J; Hall WW; Sheehy N
    J Virol; 2019 Aug; 93(16):. PubMed ID: 31142665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
    Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.